Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational statusStefano Rossetti,Aaron Broege,Ian MacNeil, Ben Rich, Jhomary Molden, Brian Sullivan,Lance LaingCANCER RESEARCH（2023）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
